Coming Soon

Autolus Limited

Registration Number 09115837

Trading name: Autolus Therapeutics

Autolus Therapeutics is a biopharmaceutical company focused on developing next-generation programmed T cell therapies for the treatment of cancer. The company utilizes its proprietary technology platform to create optimized and engineered T cell therapies that aim to provide more effective treatment options for patients with cancer.

Company Overview

Company Name
Autolus Limited
Registration Number
09115837
Founded
03 July 2014
Age
10 years
Industry Region
Unknown
Registered Postcode
W12 7FP

Online Profile

Special Flags

Spinout Company
Public Funding Received

Public Funding for Autolus Limited

2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2021-04-01
Northern Alliance ATTC
Centres
2021-04-01
Standard Approach to atMP tissue ColLEction (Sample)
Centres
2020-06-01
Design, Transfer and Qualification of a Commercially-Scalable Process for Viral Vectors
Feasibility Studies
2020-05-01
Evaluation of novel protein based disease ameliorating therapeutics
Feasibility Studies
2019-01-01
Digital Delivery of Personalised Advanced Therapies
Collaborative R&D
2018-12-01
Standard Approach to atMP tissue colLEction (SAMPLE)
Collaborative R&D
2018-03-01
Design, Transfer and Qualification of a Commercially-Scalable Process for Viral Vectors
Collaborative R&D
2018-03-01
Northern Alliance Advanced Therapies Treatment Centre
Collaborative R&D
2017-05-01
Design, Transfer and Qualification of a Commercially-Scalable Manufacturing Process for CAR-T cells
Collaborative R&D
2016-05-01
CAR Therapy for T Cell Malignancies
Collaborative R&D
2015-04-01
CAR therapy for Multiple Myeloma
Collaborative R&D

Get notified when we’re launching.

Want fast, powerful sales prospecting for UK companies? Signup below to find out when we're live.